All Stories

  1. Disease‐modifying antirheumatic drugs and risk of thyroxine‐treated autoimmune thyroid disease in patients with rheumatoid arthritis
  2. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
  3. How does current disease activity in rheumatoid arthritis affect the short-term risk of acute coronary syndrome? A clinical register based study from Sweden and Norway
  4. OP0133 DO JAKIS WORK THE BEST AMONG THOSE RA PATIENTS WHERE THEIR SAFETY CONCERNS ARE THE HIGHEST?
  5. Risk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses
  6. A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer
  7. Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application
  8. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
  9. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
  10. Federated analyses of multiple data sources in drug safety studies
  11. Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
  12. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
  13. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
  14. Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?
  15. Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
  16. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
  17. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
  18. Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
  19. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
  20. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
  21. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
  22. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
  23. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
  24. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study
  25. Comorbidities at diagnosis of rheumatoid arthritis: a population-based case-control study
  26. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
  27. Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
  28. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
  29. Response to: ‘Neuroinflammatory events after anti-TNFα therapy’ by Kaltsonoudiset al
  30. Siblings of patients with rheumatoid arthritis have an increased mortality rate: a Swedish cohort study
  31. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
  32. Blood neurofilament light levels segregate treatment effects in multiple sclerosis
  33. Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
  34. SAT0650 THE INFLUENCE OF PATIENT DEMOGRAPHICS ON DISEASE ACTIVITY MEASUREMENTS IN RHEUMATOID ARTHRITIS
  35. OP0001 Risk of malignancy in children with juvenile idiopathic arthritis: a register-based cohort study
  36. Valid and efficient subgroup analyses using nested case-control data
  37. Breaking the matching in nested case–control data offered several advantages for risk estimation
  38. Comparisons of risk prediction methods using nested case-control data
  39. Feasibility of reusing time-matched controls in an overlapping cohort
  40. European Collaborative Project on Affective Disorders